Ostem Implant Reports Q3 Operating Profit of 55.7 Billion KRW, Up 57.1% Year-on-Year

Sales Increased by 31.1% to 279.6 Billion Won, 'Quarterly Record High'
Strong Performance Both Domestically and Internationally

Osstem Implant Magok Central Research Center and Office Building Exterior. [Photo by Osstem Implant]

[Asia Economy Reporter Lee Gwan-joo] Osstem Implant announced on the 25th that its sales in the third quarter of this year reached 279.6 billion KRW, a 31.1% increase compared to the same period last year. This is the highest quarterly record ever.

Operating profit was recorded at 55.7 billion KRW, a 57.1% growth compared to the same period last year. The cumulative sales up to the third quarter increased by 32.9% to 779.1 billion KRW, and operating profit rose by 71.5% to 163.3 billion KRW.

A company official stated, "Despite various variables such as unstable international situations and China's Volume-Based Procurement (VBP) policy, we have demonstrated a stable business structure compared to global competitors by achieving outstanding external growth up to the third quarter. The possibility of achieving this year's targets of 1 trillion KRW in sales and 200 billion KRW in operating profit has significantly increased."

Osstem Implant achieved remarkable results both domestically and internationally in the third quarter. Domestic sales and operating profit increased by 43.1% and 86.2%, respectively, compared to the same period last year, leading to strong performance.

Overseas, the company achieved a sales growth rate of 36.3% in its key market, China, compared to the same period last year. In the United States, another major market, sales increased by 28.3% compared to last year.

The Asia-Pacific region, which includes countries in the market growth phase such as Russia and T?rkiye?where the effects of the differentiated direct sales system were prominent?also showed a stable growth rate in sales.

Um Tae-kwan, CEO of Osstem Implant, said, "In the long term, we will focus on expanding the number one products in domestic and international markets in implant systems that are safe and have high success rates even for patients with poor oral health, as well as in oral scanners and design software, which are core tools for completing digital dentistry. We will strengthen R&D investment to become the world’s leading dental company."

This content was produced with the assistance of AI translation services.